These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 19372556

  • 1. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
    Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ.
    Mol Cancer Ther; 2009 Apr; 8(4):834-43. PubMed ID: 19372556
    [Abstract] [Full Text] [Related]

  • 2. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ.
    Int J Cancer; 2009 Nov 15; 125(10):2332-41. PubMed ID: 19637312
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis.
    Bergeron S, Lemieux E, Durand V, Cagnol S, Carrier JC, Lussier JG, Boucher MJ, Rivard N.
    Mol Cancer; 2010 Oct 13; 9():271. PubMed ID: 20942929
    [Abstract] [Full Text] [Related]

  • 7. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
    Grasso S, Tristante E, Saceda M, Carbonell P, Mayor-López L, Carballo-Santana M, Carrasco-García E, Rocamora-Reverte L, García-Morales P, Carballo F, Ferragut JA, Martínez-Lacaci I.
    Neoplasia; 2014 Oct 13; 16(10):845-60. PubMed ID: 25379021
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.
    Hirschi B, Gallmeier E, Ziesch A, Marschall M, Kolligs FT.
    Mol Cancer; 2014 May 24; 13():122. PubMed ID: 24885690
    [Abstract] [Full Text] [Related]

  • 10. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
    Emery CM, Monaco KA, Wang P, Balak M, Freeman A, Meltzer J, Delach SM, Rakiec D, Ruddy DA, Korn JM, Haling J, Acker MG, Caponigro G.
    Mol Cancer Res; 2017 Oct 24; 15(10):1431-1444. PubMed ID: 28655712
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. ERK1/2 activation mediated by the nutlin‑3‑induced mitochondrial translocation of p53.
    Lee SY, Shin SJ, Kim HS.
    Int J Oncol; 2013 Mar 24; 42(3):1027-35. PubMed ID: 23314357
    [Abstract] [Full Text] [Related]

  • 13. A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook.
    Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ.
    Sci Signal; 2011 Mar 24; 4(170):er2. PubMed ID: 21674991
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
    Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG.
    Cancer Res; 2011 Feb 01; 71(3):1071-80. PubMed ID: 21148749
    [Abstract] [Full Text] [Related]

  • 16. Colorectal cancer cells with the BRAF(V600E) mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIM.
    Wickenden JA, Jin H, Johnson M, Gillings AS, Newson C, Austin M, Chell SD, Balmanno K, Pritchard CA, Cook SJ.
    Oncogene; 2008 Dec 04; 27(57):7150-61. PubMed ID: 18806830
    [Abstract] [Full Text] [Related]

  • 17. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
    Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC.
    Clin Cancer Res; 2014 Aug 15; 20(16):4251-61. PubMed ID: 24947927
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.
    Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J.
    J Clin Oncol; 2013 Dec 10; 31(35):e448-51. PubMed ID: 24190114
    [No Abstract] [Full Text] [Related]

  • 20. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
    Holck S, Bonde J, Pedersen H, Petersen AA, Chaube A, Nielsen HJ, Larsson LI.
    Hum Pathol; 2016 Aug 10; 54():37-46. PubMed ID: 27036313
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.